|
is a subsidiary drug manufacturer operating in Japan controlled by Hoffmann–La Roche, which owns 62% of the company as of 30 June 2014. Previous to Roche's takeover in 2002, Chugai was a pioneering discoverer of many important pharmaceutical compounds. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director, chairman, and CEO. Tatsuro Kosaka is the current representative director, president, and COO. ==History== * 1961 developed patents for synthesis of vitamin A * 1995 acute promyelocytic sphere of drug treatment leukemia Vesanoid was released. * 1996 anti-viral chemotherapeutic agent Hivid released (HIV reverse transcriptase inhibitor) * 1997 – HIV protease inhibitor Invirase released * 1999 – immunosuppressive agent Cellcept released * 2000 – Release of an antiemetic drug Kytril, developed to combat the side effects of chemotherapy * 2001 – Produced an anti-influenza virus Tamiflu (Roche) * 2015 – In March the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of $205 million.〔(【引用サイトリンク】title=GEN – News Highlights:Chugai to Co-Develop Athersys' Cell Therapy in Japan in Up-to-$205M Partnership )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Chugai Pharmaceutical Co.」の詳細全文を読む スポンサード リンク
|